Abstract: Peripheral T-cell lymphomas (PTCLs) comprise a group of highly heterogeneous, aggressive non-Hodgkin's lymphomas with a poor overall prognosis. Currently, the first- line treatment for PTCL is the cyclophosphamide+doxorubicin+ vincristine+prednisone (CHOP) regimen. However, the recurrence rate is still high. Recently, several studies have reported on the progress in first-line treatments for PTCL. These studies mainly involved the exploration of new chemotherapy regimens, trial of new drugs in combination with chemotherapy, trial of new drug combinations, and the application of autologous stem cell transplantation (ASCT). New therapeutic protocols are a source of hope to patients. Targeted therapy according to the new molecular classification may change the current treatment strategy. This article reviews the advancements in the treatment of newly diagnosed peripheral T-cell lymphoma.